• Boehringer Ingelheim Enhances Central Nervous System Disease Pipeline
• Vanderbilt Center for Neuroscience Drug Discovery Advances Preclinical Schizophrenia Targets
NASHVILLE, Tenn. & INGELHEIM, Germany-Thursday 3 January 2019 [ AETOS Wire ]
(BUSINESS WIRE) -- Boehringer Ingelheim and Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) today announced two new global agreements to investigate, develop and commercialize novel small molecules targeting two distinct G-protein coupled receptors (GPCRs) known to engage in the modulation of certain brain circuitries, which are altered in neuropsychiatric conditions such as schizophrenia.
“By joining forces with Vanderbilt University, one of the world’s leading groups integrating basic neuroscience and new translational approaches in neuropsychiatric conditions, Boehringer Ingelheim will strengthen and expand efforts to bring new treatments to patients,” said Bern
Read more »